$TLGT Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%

BUENA, N.J., Nov. 22, 2017 — Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Butyrate Lotion 0.1%.  This is Teligent’s ninth approval for 2017, and its nineteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent QuintilesIMS Health data from September 2017, the total addressable market for this product is approximately $17.0 million.

“Hydrocortisone Butyrate Lotion 0.1% is Teligent’s ninth FDA approval in 2017,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “We submitted this ANDA on August 31, 2016, pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).  As we were the first ANDA applicant to submit an ANDA with a paragraph IV certification for Hydrocortisone Butyrate Lotion, 0.1%, with this approval Teligent is eligible for 180 days of generic drug exclusivity for Hydrocortisone Butyrate Lotion, 0.1%.  We expect to launch this product in the first quarter of 2018.”

Mr. Grenfell-Gardner continued, “I would like to commend our team for delivering another first-cycle approval from the FDA in less than 15 months from our filing date.  We now have twenty-four topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company.  Our mission is to be a leading player in the specialty generic prescription drug market.  Learn more on our website www.teligent.com.

Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “plan,” “believe,” “continue,” “should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions.  These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in Teligent, Inc.’s most recent Annual Report on Form 10-K,  Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission.  Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

Contact:
Jenniffer Collins
Teligent, Inc.
(856) 697-4379
www.teligent.com